Here’s what you should know:
1. Mavyret is a once-daily, ribavirin-free treatment for adult chronic hepatitis C virus sufferers. It targets the virus across all major genotypes.
2. AbbVie conducted nine registrational studies, examining more than 2,300 patients across all major HCV genotypes. Clinical trials touted high cure rates across all patient populations.
3. AbbVie claims up to 95 percent of HCV patients would be eligible for treatment with Mavyret.
4. AbbVie executive vice president of research and development and chief scientific officer Michael Severino, MD, said in a release, “With Mavyret, physicians and patients now have a treatment option that is highly effective and has the potential to cure the majority of HCV patients in as short as eight weeks, regardless of genotype.”
More articles on gastroenterology:
Gastro Health acquires ASC & more: 3 GI practices in the news
Gastro Health acquires Gastrointestinal Center of Hialeah — 4 insights
Northwell Health Physician Partners opens multispecialty practice— 4 key notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
